A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
Giuseppe Giaccone(Cornell University), Herbert M. Pinedo(Leiden University), Nobusuke Nishi(Kirin (Japan)), Rita Ruijter(Vrije Universiteit Amsterdam), Marlies Peters(Radboud University Nijmegen), Jos H. Beijnen(The Netherlands Cancer Institute), Alfons J.M. van den Eertwegh(Amsterdam University Medical Centers), B. Mary E. von Blomberg(Vrije Universiteit Amsterdam), H. Zwierzina(Innsbruck Medical University), M. Roelvink, Rik J. Scheper(Unknown), Cornelis J. A. Punt(Radboud University Nijmegen)
PubMed
December 1, 2002
Cited by 507
Related Papers
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2009|913
Fluorouracil: biochemistry and pharmacology.
|Journal of Clinical Oncology|1988|834
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803